O
FPRX

OrbiMed’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

OrbiMed’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,075,400
Closed -$12.6M – 142
2014
Q3 		$12.6M Hold
1,075,400
– – 0.13% 93
2014
Q2 		$16.7M Hold
1,075,400
– – 0.2% 70
2014
Q1 		$21.1M Buy
+1,075,400
New +$18.3M 0.26% 64

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

OrbiMed's FPRX Position: Q4 2014 in Review

OrbiMed sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2014, closing a stake of 1,075,400 shares — an estimated $12.6M sold.

OrbiMed first reported a position in FPRX in Q1 2014 and held it in 3 quarters. The position peaked at $21.1M in Q1 2014. 71 funds tracked by Wall St. Rank hold FPRX as of Q4 2014.

  • OrbiMed reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • OrbiMed sold 1,075,400 Five Prime Therapeutics, Inc. shares in Q4 2014, an estimated $12.6M.
  • OrbiMed first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • OrbiMed's Five Prime Therapeutics, Inc. position peaked at $21.1M in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2014.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.